This discrepancy has been ascribed, in part, to the observation that ATP-competitive HSP90 inhibitors promote the HSR and result in the increased expression of HSP70, HSP27, and other pro-survival components34,35, possibly offsetting any anti-cancer benefit of these drugs. The gene discussed is HSP90AB1; the disease is cancer.